Plain-English translation of NCT06758024 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a smarter way to give , a biologic medication that helps calm down severe gut inflammation in Crohn's disease and ulcerative colitis. Instead of using standard doses for everyone, the study checks blood levels of the medication early on and adjusts doses using a computer model to help get each patient to the right amount. The goal is to help more patients respond well to the treatment and avoid losing its effectiveness over time.
Many patients don't respond well to this medication from the start, or they stop responding after a while—partly because drug levels in their blood become too low. Low levels can also cause the body to develop antibodies that attack the medication itself, making it stop working or even cause serious allergic reactions. This trial wants to see if catching and fixing low drug levels early can prevent these problems.
You likely qualify if…
You likely don't qualify if…
You will receive infusions as part of your regular treatment for your flare. If you are randomly assigned to the new approach, your doctors will check your blood levels of the medication at week 2 and week 6, and a computer tool will suggest personalized dose adjustments to help you reach the target blood level. If you are in the standard care group, you will receive regular doses with only clinical judgment guiding any changes. Throughout the study, you'll work with your hospital team to track how well the treatment is working.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Chile